Your browser doesn't support javascript.
loading
PIK3CA mutations are associated with pathologic complete response rate to neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer.
Shi, Qiyun; Xuhong, Juncheng; Luo, Tao; Ge, Jia; Liu, Feng; Lan, Yang; Chen, Qingqiu; Tang, Peng; Fan, Linjun; Chen, Li; Liang, Yan; Wang, Minghao; Hu, Ying; Zhang, Yi; Bian, Xiuwu; Qi, Xiaowei; Jiang, Jun.
Afiliação
  • Shi Q; Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University, 400038, Chongqing, China.
  • Xuhong J; Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University, 400038, Chongqing, China.
  • Luo T; Shigatse Branch, Xinqiao Hospital, Army Medical University, 857000, Shigatse, China.
  • Ge J; Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Army Medical University, 400038, Chongqing, China.
  • Liu F; Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Army Medical University, 400038, Chongqing, China.
  • Lan Y; Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Army Medical University, 400038, Chongqing, China.
  • Chen Q; Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Army Medical University, 400038, Chongqing, China.
  • Tang P; Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University, 400038, Chongqing, China.
  • Fan L; Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University, 400038, Chongqing, China.
  • Chen L; Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University, 400038, Chongqing, China.
  • Liang Y; Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University, 400038, Chongqing, China.
  • Wang M; Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University, 400038, Chongqing, China.
  • Hu Y; Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University, 400038, Chongqing, China.
  • Zhang Y; Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University, 400038, Chongqing, China.
  • Bian X; Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University, 400038, Chongqing, China.
  • Qi X; Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Army Medical University, 400038, Chongqing, China. bianxiuwu@263.net.
  • Jiang J; Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University, 400038, Chongqing, China. qxw9908@foxmail.com.
Br J Cancer ; 128(1): 121-129, 2023 01.
Article em En | MEDLINE | ID: mdl-36323880
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article